Date | Price Target | Rating | Analyst |
---|---|---|---|
9/10/2024 | $60.00 | Buy | Truist |
7/1/2024 | $60.00 → $90.00 | Overweight | Cantor Fitzgerald |
5/1/2024 | $36.00 | Outperform | Robert W. Baird |
2/16/2024 | $40.00 | Buy | Citigroup |
10/24/2023 | $16.00 → $35.00 | Overweight | Cantor Fitzgerald |
4/27/2023 | $13.00 | Buy | B. Riley Securities |
2/14/2022 | $14.00 | Outperform | Wedbush |
U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation and Rare Pediatric Disease designation for bexicaserin for the treatment of Dravet syndrome Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Rare Pediatric Disease designation and Orphan Drug designation for its investigational drug bexicaserin for the treatment of Dravet syndrome. "We are thrilled to receive both Rare Pediatric Disease and Orphan Drug designations for bexicaserin in Dravet syndrome. As the first company to receive Breakthrough Therapy
Bexicaserin achieved an overall median seizure reduction of 57.7% in countable motor seizures over an approximate 9-month treatment period Favorable safety and tolerability results continue to be observed Data to be presented at the 15th European Epilepsy Congress in Rome, Italy Full 12-month OLE dataset expected early next year Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Develop
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to eleven new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 203,500 shares of its common stock (the "Common Stock") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted on August 31, 2024 (the "Grant Date") and have an exercise price of $36.08 per share, wh
Truist initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $60.00
Cantor Fitzgerald reiterated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $90.00 from $60.00 previously
Robert W. Baird initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $36.00
SC 13G - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older Bexicaserin demonstrated a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEEs in an interim analysis of the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Completed End of Phase 2 Meeting to discuss Longboard's global Phase 3 program for bexicaserin, which is on track to initiate in H2 2024 Longboard plans to host an Investor & Analyst Event on September 16 to highlight details of the global P
Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a conference call and we
Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in Dravet Syndrome (DS), 48.1% in Lennox-Gastaut Syndrome (LGS) and 61.2% in DEE Other was achieved Favorable safety and tolerability results Longboard is rapidly moving forward with preparations for its global Phase 3 program Conference call and webcast to be held today at 8:30am ET Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline da
Baird analyst Joel Beatty maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $36 to $60.
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Harrow Inc (NASDAQ:HROW) On June 21, Craig-Hallum analyst Chase Knickerbocker maintained Har
Citigroup analyst David Hoang maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price target from $40 to $45.
144 - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
144 - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
10-Q - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Dr. Randall Kaye as Chief Medical Officer (CMO). Dr. Philip Perera, who has led the clinical development and medical affairs activities since the launch of Longboard, has retired as CMO while remaining with Longboard in an advisory role. "On behalf of the board, shareholders, and our employees, I want to thank Phil for his tremendous contributions," said Kevin R. Lind, Longboard's President and Chief Executive Officer. "His outstanding leade
Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndromeLP659 IND submission remains on track for second half of 2022Cash position expected to support operations into 2024 based on current business plan SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financ
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors. "We are thrilled to further strengthen the deep expertise of our Board with the addition of Dr. Tiller. Jane brings knowledge across multiple therapeutic areas including neuroscience, and a deep understanding and successful track record in strategy and execution in global clinical development and medical affairs," stated Kevin R. Lind, Longboard's President and Chief Executive Officer.